How Did These Data Get Here? Recommendations for the Analysis of Data From ClinicalTrials.gov
Abstract A paper by Drs Okada and Sengoku that appears in this issue of TIRS shows how data from Clinicaltrials.gov can be used for research on the pharmaceutical industry. This commentary identifies several challenges associated with using these data for research and concludes with 3 recommendations from a statistical perspective..
| Medienart: |
Artikel |
|---|
| Erscheinungsjahr: |
2019 |
|---|---|
| Erschienen: |
2019 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:53 |
|---|---|
| Enthalten in: |
Therapeutic innovation & regulatory science - 53(2019), 5 vom: Sept., Seite 639-640 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Durham, Todd A. [VerfasserIn] |
|---|
| Links: |
Volltext [lizenzpflichtig] |
|---|
| Themen: |
|---|
| Anmerkungen: |
© Drug Information Association, Inc 2018 |
|---|
| doi: |
10.1177/2168479018811825 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
OLC209577986X |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | OLC209577986X | ||
| 003 | DE-627 | ||
| 005 | 20240408161705.0 | ||
| 007 | tu | ||
| 008 | 230331s2019 xx ||||| 00| ||eng c | ||
| 024 | 7 | |a 10.1177/2168479018811825 |2 doi | |
| 035 | |a (DE-627)OLC209577986X | ||
| 035 | |a (DE-He213)2168479018811825-p | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 082 | 0 | 4 | |a 610 |q VZ |
| 084 | |a PHARM |q DE-84 |2 fid | ||
| 084 | |a 15,3 |2 ssgn | ||
| 100 | 1 | |a Durham, Todd A. |e verfasserin |0 (orcid)0000-0002-0363-0329 |4 aut | |
| 245 | 1 | 0 | |a How Did These Data Get Here? Recommendations for the Analysis of Data From ClinicalTrials.gov |
| 264 | 1 | |c 2019 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ohne Hilfsmittel zu benutzen |b n |2 rdamedia | ||
| 338 | |a Band |b nc |2 rdacarrier | ||
| 500 | |a © Drug Information Association, Inc 2018 | ||
| 520 | |a Abstract A paper by Drs Okada and Sengoku that appears in this issue of TIRS shows how data from Clinicaltrials.gov can be used for research on the pharmaceutical industry. This commentary identifies several challenges associated with using these data for research and concludes with 3 recommendations from a statistical perspective. | ||
| 650 | 4 | |a Clinicaltrials.gov | |
| 650 | 4 | |a observational research | |
| 773 | 0 | 8 | |i Enthalten in |t Therapeutic innovation & regulatory science |d Springer International Publishing, 2013 |g 53(2019), 5 vom: Sept., Seite 639-640 |w (DE-627)723899584 |w (DE-600)2680237-5 |w (DE-576)435514075 |x 2168-4790 |7 nnns |
| 773 | 1 | 8 | |g volume:53 |g year:2019 |g number:5 |g month:09 |g pages:639-640 |
| 856 | 4 | 1 | |u https://doi.org/10.1177/2168479018811825 |z lizenzpflichtig |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a SYSFLAG_A | ||
| 912 | |a GBV_OLC | ||
| 912 | |a FID-PHARM | ||
| 912 | |a SSG-OLC-PHA | ||
| 912 | |a SSG-OPC-PHA | ||
| 912 | |a SSG-OPC-DE-84 | ||
| 951 | |a AR | ||
| 952 | |d 53 |j 2019 |e 5 |c 09 |h 639-640 | ||